SST and prostate cancer: In the case of SST, its synthetic analogs (e.g., octreotide and lanreotide) have been shown to inhibit the proliferation of several tumor-derived cell lines in vitro [5], and to reduce tumor progression in vivo in studies using preclinical models of breast and prostate cancer [42].